10 Biotechnology Stocks to Sell Now

10 Biotechnology Stocks to Sell Now

This week, the overall grades of 10 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Alexion Pharmaceuticals, Inc.’s (ALXN) rating weakens this week, dropping to a D versus last week’s C. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

This week, Cepheid’s (CPHD) rating worsens to a F from the company’s D rating a week ago. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. The company also gets F’s in earnings growth and return on equity. For more information, get Portfolio Grader’s complete analysis of CPHD stock.

Enanta Pharmaceuticals, Inc. (ENTA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ENTA stock.

Ascendis Pharma A/S Sponsored ADR (ASND) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of ASND stock.

Slipping from a C to a D rating, Invitae Corp. (NVTA) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

This week, Enzymotec Ltd. (ENZY) drops from a C to a D rating. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

CoLucid Pharmaceuticals, Inc. (CLCD) slips from a C to a D this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLCD stock.

Galmed Pharmaceuticals Ltd. (GLMD) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GLMD stock.

Asterias Biotherapeutics Inc Class A (AST) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AST stock.

Prima BioMed Ltd Sponsored ADR (PBMD) earns a F this week, moving down from last week’s grade of B. Prima BioMed Ltd Sponsored ADR a biotechnology company, researches, develops, and commercializes licensed medical biotechnology products in Australia. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PBMD stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/10-biotechnology-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC